Provided by Tiger Trade Technology Pte. Ltd.

Bausch + Lomb Corp.

15.65
+0.06000.38%
Post-market: 15.740.0900+0.58%18:37 EDT
Volume:819.82K
Turnover:12.82M
Market Cap:5.58B
PE:-25.18
High:15.71
Open:15.55
Low:15.43
Close:15.59
52wk High:18.92
52wk Low:11.22
Shares:356.38M
Float Shares:42.05M
Volume Ratio:2.59
T/O Rate:1.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6214
EPS(LYR):-1.0200
ROE:-3.28%
ROA:1.42%
PB:0.87
PE(LYR):-15.34

Loading ...

Bausch + Lomb Director Karen Ling Acquires Common Shares

Reuters
·
Feb 24

Bausch + Lomb : Deutsche Bank Raises Target Price to $18 From $15

THOMSON REUTERS
·
Feb 19

Bausch + Lomb (BLCO) Loss Narrows To US$28m As Margin Repair Narrative Gains Traction

Simply Wall St.
·
Feb 19

Bausch Health posts Q4 adjusted EBITDA of USD 1.05B, up 13%

Reuters
·
Feb 19

Analysts Have Conflicting Sentiments on These Healthcare Companies: ImmunityBio (IBRX) and Bausch + Lomb Corporation (BLCO)

TIPRANKS
·
Feb 19

Stock Track | Bausch + Lomb Plummets 5.47% Intraday Following Q4 Earnings Miss

Stock Track
·
Feb 18

Bausch + Lomb Q4 Adjusted EBITDA USD 326 Million Vs. IBES Estimate USD 320.4 Million

Reuters
·
Feb 18

Bausch + Lomb Q4 revenue beats estimates, helped by Vision Care segment

Reuters
·
Feb 18

GUIDANCE: (BLCO) Bausch + Lomb Expects 2026 Revenue Range $5.38B - $5.48B, vs. FactSet Est of $5.39B

MT Newswires Live
·
Feb 18

Bausch & Lomb Q4 Adj. EPS $0.32 Misses $0.35 Estimate, Sales $1.405B Beat $1.381B Estimate

Benzinga
·
Feb 18

Bausch + Lomb Q4 Pharmaceuticals revenue jumps 16% to USD 378 million

Reuters
·
Feb 18

Stifel Nicolaus Keeps Their Hold Rating on Bausch + Lomb Corporation (BLCO)

TIPRANKS
·
Feb 17

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 17

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 13

How Bausch + Lomb’s Mandatory AI Academy Could Reshape BLCO’s Digital Execution Narrative

Simply Wall St.
·
Feb 13

Earning Preview: Bausch + Lomb Corp. Q4 revenue is expected to increase by 9.79%, institutional views are constructive

Earnings Agent
·
Feb 11

Bausch + Lomb Likely to Report a Q4 Beat on FX Tailwinds, Robust Performance of Eye Disease Portfolio, RBC Says

MT Newswires Live
·
Jan 28

RBC Raises Price Target on Bausch + Lomb to $21 From $19, Keeps Outperform Rating

MT Newswires Live
·
Jan 27

Bausch + Lomb Corp. to Release Fourth-Quarter and Full-Year 2025 Financial Results

Reuters
·
Jan 20

Bausch Health Reaffirms 2025 Guidance at High End of Range

Reuters
·
Jan 13